Stereotactic radiosurgery as adjuvant or salvage treatment for sporadic hemangioblastomas: A multi-center international study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tos Salem M, Maroufi S Farzad, Hajikarimloo Bardia, Shaaban Ahmed, Mantziaris Georgios, Pham Duy, Dayawansa Sam, Nabeel Ahmed M, Reda Wael A, Tawadros Sameh R, AbdelKarim Khaled, El-Shehaby Amr M N, Emad Reem M, Wei Zhishuo, McKendrick Lindsay M, Niranjan Ajay, Lunsford L Dade, Peker Selcuk, Samanci Yavuz, Liscak Roman, May Jaromir, Mathieu David, Lee Cheng-Chia, Yang Huai-Che, Dono Antonio, Blanco Angel I, Esquenazi Yoshua, Moreno Nuria Martinez, Álvarez Roberto Martinez, Picozzi Piero, Franzini Andrea, Tripathi Manjul, Sumi Takuma, Uzuka Takeo, Kano Hideyuki, Bailey David, Zacharia Brad E, Cifarelli Christopher P, Cifarelli Daniel T, Hack Joshua D, Speckter Herwin, Lazo Erwin, Warnick Ronald E, Schoenhals Jonathan E, Palmer Joshua D, Ishaque Mariam, Asthagiri Ashok, Xu Zhiyuan, Sheehan Jason P
Аннотация
METHODS: We retrospectively analyzed 82 patients with sporadic hemangioblastomas treated with GKRS across 17 International Radiosurgery Research Foundation centers (1993-2022). Univariate and multivariate analysis was conducted to identify variables influencing local control and tumor regression.
RESULTS: Among 82 patients (52.4 % male, median age 51.5 years [IQR: 40.3-63.0]), most tumors were cerebellar (70.7 %), solid (63.4 %), with a median volume of 1.8 cc [IQR: 0.8-6.1]. The median margin dose was 16.0 Gy [IQR: 14.0-18.0]. With a median follow-up of 51.5 months [IQR: 21.0-92.0], local control was achieved in 69.5 % of cases (40.2 % regression, 29.3 % stability). Local control rates were 95 % (90 %, 100 %) at 6 months but declined to 75 % (65 %, 87 %) at 60 months. Radiation necrosis occurred in 6.1 % of patients (5/82), and no tumor-related deaths were reported among the 11.1 % overall mortality. Brainstem location was significantly linked to lower odds of tumor regression in the multivariate analysis (OR: 0.29, 95 % CI: 0.09-0.98, p = 0.045).
CONCLUSION: GKRS demonstrated efficacy and safety in treating sporadic hemangioblastomas, achieving reasonable long-term local control rates with minimal complications. Our findings support its role as a viable treatment option, particularly for surgically challenging cases.